Overall, based on our in vivo and patient data, we suggest a clinical pathway incorporating phospho-MET IHC staining in addition to standard MET FISH assays to guide treatment for patients with osimertinib-resistant EGFR-mutant lung cancer (Fig. 5C). This evidence concerns the gene EGFR and lung carcinoma.